<SEC-DOCUMENT>0001714899-26-000096.txt : 20260806
<SEC-HEADER>0001714899-26-000096.hdr.sgml : 20260806
<ACCEPTANCE-DATETIME>20260806160319
ACCESSION NUMBER:		0001714899-26-000096
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20260806
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260806
DATE AS OF CHANGE:		20260806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Denali Therapeutics Inc.
		CENTRAL INDEX KEY:			0001714899
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				463872213
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38311
		FILM NUMBER:		261248769

	BUSINESS ADDRESS:	
		STREET 1:		161 OYSTER POINT BLVD.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 866-8547

	MAIL ADDRESS:	
		STREET 1:		161 OYSTER POINT BLVD.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dnli-20260806.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019fd389-18b2-7284-ba9c-b5321995517e,g:d322ee95-5970-4db4-b30b-d93f59966936,d:f08728067fa44125bcb33b3cff00a659-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>dnli-20260806</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001714899</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="dnli-20260806.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-08-06</xbrli:startDate><xbrli:endDate>2026-08-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if08728067fa44125bcb33b3cff00a659_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): </span></div><div style="margin-bottom:2pt;margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August&#160;6, 2026</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Denali Therapeutics Inc.</ix:nonNumeric></span></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.774%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38311</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">46-3872213</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">incorporation)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File Number)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">161 Oyster Point Blvd.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94080</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">866-8547</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last reports)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.415%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.966%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol (s) </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">DNLI</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:111.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:13.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:381.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:32pt"><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    &#9744;</span></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.639%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if08728067fa44125bcb33b3cff00a659_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02 &#160;&#160;&#160;&#160;Results of Operations and Financial Condition. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;6, 2026, Denali Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2026. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit&#160;99.1) shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:11.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.930%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex991pressreleaseq22026.htm">Press Release dated August 6, 2026.</a></span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL)</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if08728067fa44125bcb33b3cff00a659_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="text-align:justify;text-indent:37pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.747%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENALI THERAPEUTICS INC.</span></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 6, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Alexander O. Schuth</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alexander O. Schuth, M.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Operating and Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991pressreleaseq22026.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i62dfc679b4224d3aa92e28cb2b959584_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">99.1</font></div></div><div><img alt="denali_greenlogo.jpg" src="denali_greenlogo.jpg" style="height:52px;margin-bottom:5pt;vertical-align:text-bottom;width:249px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">Strong first full quarter of AVLAYAH&#8482; (tividenofusp alfa-eknm) launch generated $3.6 million in net product revenue</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">Advanced TransportVehicle&#8482; portfolio with two Alzheimer&#8217;s disease programs now in clinical development</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">$195 million in gross proceeds received in July 2026 from sale of a Priority Review Voucher, bringing pro forma cash, cash equivalents and marketable securities to more than $1.1 billion</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">Conference call and webcast today at 4&#58;30 p.m. ET</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:116%">SOUTH SAN FRANCISCO, Calif. &#8211; August&#160;6, 2026 &#8211;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:116%">&#160;Denali Therapeutics Inc. (Nasdaq&#58; DNLI) today reported financial results for the second quarter ended June 30, 2026, and provided business highlights. </font></div><div id="i62dfc679b4224d3aa92e28cb2b959584_4"></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#34;We are excited by the positive response to our AVLAYAH launch from the Hunter syndrome community and the physicians caring for these patients. It reflects years of partnership with patients, families, advocacy organizations and investigators, together with the outstanding execution of our commercial team,&#34; said Ryan Watts, Ph.D., Chief Executive Officer of Denali Therapeutics. &#34;This quarter marks an important step in Denali's growth. AVLAYAH establishes our commercial foundation, validates our TransportVehicle platform and supports the continued expansion of our portfolio of medicines. During the quarter, we also advanced two TransportVehicle-enabled programs into clinical development, expanding our Alzheimer's disease pipeline. We believe this combination of a commercial business, a broad clinical pipeline and a scalable platform uniquely positions Denali to deliver sustainable value.&#34; </font></div><div id="i62dfc679b4224d3aa92e28cb2b959584_7"></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Second Quarter 2026 and Recent Program Updates</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMMERCIAL PRODUCT</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AVLAYAH for Hunter syndrome (MPS II) </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVLAYAH (tividenofusp alfa-eknm) is the first and only FDA-approved medicine in the emerging class of biotherapeutics that leverage the transferrin receptor to cross the blood-brain barrier. Enabled by Denali's Enzyme TransportVehicle</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8482; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (ETV), AVLAYAH is an enzyme replacement therapy designed to systemically deliver iduronate 2-sulfatase (IDS) throughout the body, including the brain. AVLAYAH received U.S. Food and Drug Administration (FDA) accelerated approval for the treatment of neurologic manifestations of Hunter syndrome (mucopolysaccharidosis type II, or MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The U.S. launch of AVLAYAH demonstrated strong momentum during its first full quarter of commercial availability, supported by positive engagement from patients, caregivers and physicians, the experiences of families beginning treatment, and the rapid expansion of payer coverage.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">In its first full quarter of commercial availability, AVLAYAH generated $3.6 million in net product revenue. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Projected third-quarter 2026 AVLAYAH net product revenue is $10.0 million to $12.0 million.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Initial interest in starting treatment with AVLAYAH has tracked ahead of Denali&#8217;s internal expectations.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Approximately 80% of healthcare organizations that treat eligible MPS II patients have been reached through AVLAYAH launch webinars and engagement with Denali's field team.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Commercial access to AVLAYAH expanded rapidly. Published commercial policies now represent more than 50% of covered lives, and 14 state Medicaid programs have published coverage of AVLAYAH.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Denali continues to advance U.S. launch execution across patient access services, physician engagement and payer access, supported by a fully established commercial infrastructure.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The ongoing global Phase 2&#47;3 COMPASS study is intended to support generation of confirmatory evidence, expansion of the U.S. label to adult patients and future global regulatory submissions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CLINICAL PROGRAMS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lysosomal Storage Diseases</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Zafinofusp alfa (DNL126&#59; ETV&#58;SGSH) for Sanfilippo syndrome type A (MPS IIIA)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Zafinofusp alfa is an investigational ETV-enabled enzyme replacement therapy designed to systemically deliver N-sulfoglucosamine sulfohydrolase (SGSH) throughout the body, including the brain, for the treatment of Sanfilippo syndrome type A. There are currently no approved therapies for Sanfilippo syndrome type A. Preliminary data from the ongoing Phase 1&#47;2 study demonstrated that treatment with zafinofusp alfa resulted in substantial reductions in both cerebrospinal fluid (CSF) and urine heparan sulfate (HS), including normalization of CSF HS, with a safety profile generally consistent with established enzyme replacement therapies. Start-up activities are underway for a global Phase 3 confirmatory study. Denali expects a Biologics License Application (BLA) submission and potential accelerated approval for zafinofusp alfa for Sanfilippo syndrome type A in 2027.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DNL593 (PTV&#58;PGRN) for FTD-</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GRN</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">DNL593 is an investigational Protein TransportVehicle</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8482;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (PTV)-enabled protein replacement therapy designed to systemically deliver progranulin (PGRN) across the blood-brain barrier for the treatment of granulin (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">GRN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)-related frontotemporal dementia (FTD-</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">GRN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">). In August 2026, the FDA granted Orphan Drug Designation to DNL593 for FTD-</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">GRN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, underscoring the significant unmet need facing individuals affected by this disease. Enrollment in the Phase 1&#47;2 study of DNL593 is complete with a total of 40 participants with FTD-</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">GRN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Denali now expects results from the study in 2027, updated from its prior expectation of results by the end of 2026. The revised timing allows for a longer observation period to assess the treatment effect on biomarkers including neurofilament light chain (NfL), a biomarker of neuroaxonal injury that may decline gradually following treatment, as observed in other neurodegenerative diseases.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DNL952 (ETV&#58;GAA) for Pompe disease</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">DNL952 is an investigational ETV-enabled enzyme replacement therapy designed to systemically deliver acid alpha-glucosidase (GAA) to muscle tissue and the brain by crossing the blood-brain barrier for the treatment of Pompe disease. The current standard of care is enzyme replacement therapy. Progressive motor weakness, respiratory failure and neurologic symptoms remain unmet needs. Dosing of participants with late-onset Pompe disease began in the Phase 1 study of DNL952 in the second quarter of 2026, and initial clinical data are expected in 2027.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Alzheimer's Disease</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2026, Dr. Watts delivered the opening plenary address, &#34;Accelerating the Discovery and Development of Medicines for Neurodegeneration,&#34; at the Alzheimer's Association International Conference</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in London. The presentation highlighted advances in disease biology, biomarkers and blood-brain barrier delivery, as well as progress across Denali's two clinical-stage Alzheimer's disease programs, DNL628 (OTV&#58;MAPT) and DNL921 (ATV&#58;Abeta).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DNL628 (OTV&#58;MAPT) for Alzheimer's disease</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">DNL628 is an investigational Oligonucleotide TransportVehicle</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8482;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (OTV)-enabled antisense oligonucleotide designed for systemic delivery across the blood-brain barrier to reduce tau by targeting the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">MAPT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> gene for the treatment of Alzheimer&#8217;s disease. Initial clinical biomarker data from the ongoing Phase 1b study of DNL628 in participants with Alzheimer&#8217;s disease are expected in the first half of 2027. </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DNL921 (ATV&#58;Abeta) for Alzheimer's disease</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">DNL921 is an investigational Antibody TransportVehicle</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8482;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (ATV)-enabled antibody designed for systemic delivery across the blood-brain barrier to target amyloid plaques in Alzheimer's disease. Safety and clinical proof-of-concept data from the ongoing Phase 1&#47;1b study of DNL921 in healthy volunteers and participants with Alzheimer's disease are expected in 2027.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Parkinson&#8217;s Disease</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DNL151 (LRRK2 inhibitor) for Parkinson's disease </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">DNL151 is an investigational small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease. In May 2026, Denali and Biogen announced that the global Phase 2b LUMA study of DNL151 did not meet its primary or secondary endpoints in early-stage Parkinson's disease. Based on these results, Denali and Biogen decided to discontinue further development of DNL151 in idiopathic Parkinson's disease. Denali continues to independently conduct the Phase 2a BEACON study evaluating DNL151 in individuals with Parkinson's disease who are confirmed by genetic testing to be carriers of a pathogenic LRRK2 variant. Data from BEACON are expected in the first half of 2027. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IND-ENABLING STAGE PROGRAMS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Denali has multiple additional programs in the investigational new drug (IND)-enabling stage, including DNL111 (ETV&#58;GCase) for Parkinson's disease and Gaucher disease&#59; DNL622 (ETV&#58;IDUA) for MPS I&#59; and DNL422 (OTV&#58;SNCA) for Parkinson's disease.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Updates</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2026, Denali announced that it had received notification of Takeda&#8217;s decision to terminate the companies&#8217; collaboration agreement to co-develop and co-commercialize DNL593. Takeda&#8217;s decision was driven by strategic considerations and was not related to efficacy or safety data. Denali continues to advance DNL593 in the ongoing Phase 1&#47;2 study in patients with FTD-</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">GRN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and now expects results in 2027 as described above.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2026, Denali entered into an agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV), awarded following the FDA approval of AVLAYAH, for gross proceeds of $195 million. The transaction closed and Denali received the funds in July 2026.    </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Participation in Upcoming Investor Conferences</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Cantor Global Healthcare Conference 2026, September 9-11 (New York) </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Morgan Stanley 24th Annual Global Healthcare Conference, September 14-16 (New York) </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">H.C. Wainwright 28th Annual Global Investment Conference, September 14-16 (New York)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Baird Global Healthcare Conference, September 15 (New York)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Deutsche Bank&#8217;s 2026 Healthcare Summit, September 16-17 (New York)</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><div id="i62dfc679b4224d3aa92e28cb2b959584_10"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Second Quarter 2026 Financial Results</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net product revenue was $3.6 million for the quarter ended June 30, 2026, reflecting the commencement of commercial sales of AVLAYAH in the United States following FDA approval in March 2026.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cost of goods sold was $0.1 million for the quarter ended June 30, 2026. Because manufacturing costs incurred prior to FDA approval of AVLAYAH were expensed to research and development, cost of goods sold during the initial commercialization period reflects a lower average per-unit cost as previously expensed inventory is sold.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total research and development expenses were $97.0&#160;million for the quarter ended June 30, 2026, compared to $102.7&#160;million for the quarter ended June 30, 2025. The decrease of approximately $5.7&#160;million was primarily attributable to lower costs related to small molecule programs as well as lower clinical expenses for tividenofusp alfa.   </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Selling, general and administrative expenses were $36.3 million for the quarter ended June 30, 2026, compared to $32.3 million for the quarter ended June 30, 2025. The increase of approximately $4.0 million was primarily driven by higher personnel-related costs due to increased headcount to support the commercial launch of AVLAYAH.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Intangible asset amortization was $0.7 million for the quarter ended June 30, 2026, compared to zero for the quarter ended June 30, 2025, reflecting amortization of the developed technology intangible asset recognized upon FDA approval of AVLAYAH in March 2026.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net loss was $127.6 million for the quarter ended June 30, 2026, compared to net loss of $124.1&#160;million for the quarter ended June 30, 2025.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash, cash equivalents and marketable securities were approximately $940.0 million as of June 30, 2026. Following the receipt of $195.0 million in gross proceeds from the sale of a Priority Review Voucher in July 2026, pro forma cash, cash equivalents and marketable securities exceeded $1.1 billion.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Conference Call and Webcast Information</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Denali will host a conference call today, Thursday, August 6, 2026, at 4&#58;30 p.m. Eastern Time to discuss the second quarter financial results and provide a corporate update. The live and replayed webcast of the call will be available through Denali&#8217;s website at https&#58;&#47;&#47;investors.denalitherapeutics.com&#47;events. The replay of the call will be available for 90 days.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">About the Denali TransportVehicle</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> Platform</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The blood-brain barrier (BBB) is essential in maintaining the brain&#8217;s microenvironment and protecting it from harmful substances and pathogens circulating in the bloodstream. Historically, the BBB has posed significant challenges to drug development for central nervous system diseases by preventing most drugs from reaching the brain in therapeutically relevant concentrations. Denali&#8217;s TransportVehicle&#8482; (TV) platform is a proprietary technology designed to effectively deliver large therapeutic molecules such as antibodies, enzymes and oligonucleotides throughout the whole body, including the brain, by crossing the BBB after intravenous administration. The TV platform is based on engineered Fc domains that bind to specific natural transport receptors, such as transferrin receptor and CD98 heavy chain amino acid transporter, which are expressed at the BBB and deliver the TV and its therapeutic cargo to the brain through receptor-mediated transcytosis. In animal models, antibodies and enzymes engineered with the TV platform demonstrate more than 10- to 30-fold greater brain exposure than similar antibodies and enzymes without this technology. Oligonucleotides engineered with the TV platform demonstrate more than a 1,000-fold greater brain exposure in primates than systemically delivered oligonucleotides without this technology. Improved exposure and broad distribution in the brain may increase therapeutic efficacy by enabling widespread achievement of therapeutically relevant concentrations of product candidates. The TV platform has been clinically validated, with AVLAYAH&#8482; (tividenofusp alfa-eknm) as the first FDA-approved medicine leveraging transferrin receptor to cross the BBB.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Denali Therapeutics</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Denali Therapeutics Inc. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier (BBB) using its proprietary TransportVehicle&#8482; platform. With the first FDA-approved biologic specifically designed to cross the BBB, a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, Denali is advancing toward its goal of delivering effective medicines to transform life for people with neurodegenerative diseases, lysosomal storage disorders and other serious diseases. For more information, please visit www.denalitherapeutics.com.</font></div><div><font><br></font></div><div><font><br></font></div><div id="i62dfc679b4224d3aa92e28cb2b959584_13"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Forward-Looking Statements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations for Denali&#8217;s TransportVehicle&#8482; (TV) platform, including the Enzyme TransportVehicle&#8482; (ETV) franchise, and its therapeutic and commercial potential&#59; plans, timelines and expectations relating to AVLAYAH&#8482; (tividenofusp alfa-eknm)&#59; expectations related to the ongoing Phase 2&#47;3 COMPASS study of tividenofusp alfa, including the timing and availability of data and the likelihood that it will generate confirmatory evidence to support continued approval, U.S. label expansion and global regulatory submissions&#59; plans, timelines and expectations related to zafinofusp alfa, including with respect to the ongoing Phase 1&#47;2 study and the planned Phase 3 confirmatory study, the timing and occurrence of a planned BLA submission, and the likelihood and timing of accelerated approval&#59; plans, timelines and expectations related to DNL593, including the ongoing Phase 1&#47;2 study, the timing and availability of data, and the potential benefits of the extended data period&#59; plans, timelines and expectations related to DNL952 and the timing and availability of data from the ongoing Phase 1 study&#59; plans, timelines and expectations related to DNL628, including the ongoing Phase 1b study and the timing and availability of clinical biomarker data&#59; plans, timelines and expectations related to DNL921, including the Phase 1&#47;1b study and the timing and availability of data&#59; plans, timelines and expectations related to DNL151, including the timing and availability of data from the ongoing Phase 2a BEACON study&#59; plans, timelines and expectations for IND-enabling stage programs&#59; plans regarding participation in upcoming investor conferences&#59; forecasts of future revenues and operating expenses&#59; and statements by Denali's Chief Executive Officer. Actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of risks and uncertainties. These include, but are not limited to, risks arising from adverse economic conditions and their impact on Denali&#8217;s business and operations&#59; the possibility of events or changes that could lead to the termination of Denali&#8217;s collaboration agreements&#59; the ability of Denali to complete the development and, if approved, the commercialization of product candidates&#59; reliance on third-party manufacturers and suppliers for clinical trial and commercial materials&#59; difficulties in patient enrollment for ongoing and future clinical trials&#59; potential delays or failures in meeting expected clinical trial timelines&#59; discrepancies between preclinical, early-stage or preliminary clinical results and outcomes from later-stage trials&#59; the risk that interim or topline clinical results may not be predictive of final study results or longer term outcomes&#59; the occurrence of significant adverse events or other undesirable side effects&#59; the uncertainty surrounding regulatory approvals required for commercialization in the U.S., Europe or other international jurisdictions, including uncertainties related to the FDA&#8217;s policies&#59; developments relating to Denali's competitors and competing product candidates&#59; Denali&#8217;s ability to obtain, maintain or protect intellectual property rights related to its product candidates&#59; the implementation and success of Denali&#8217;s strategic plans for its business, product candidates and blood-brain barrier platform technology&#59; Denali's ability to obtain additional capital to finance its operations, as needed&#59; Denali's ability to accurately forecast future revenues and operating expenses in the current environment&#59; and other risks and uncertainties, including those described in Denali's Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 26, 2026, its Quarterly Report on Form 10-Q filed with the SEC on May 7, 2026, and Denali&#8217;s future reports to be filed with the SEC. Except for AVLAYAH, Denali's product candidates are investigational, and their safety and efficacy profiles have not yet been established. Denali does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results or to make changes in Denali&#8217;s expectations, except as required by law.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="i62dfc679b4224d3aa92e28cb2b959584_16"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denali Therapeutics Inc.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except share and per share amounts)</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.049%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net</font></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,604&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,604&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,604&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,604&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of goods sold</font></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97,019&#160;</font></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102,696&#160;</font></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200,865&#160;</font></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218,923&#160;</font></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,283&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,267&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,794&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61,620&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible asset amortization</font></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750&#160;</font></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750&#160;</font></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134,145&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134,963&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271,502&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280,543&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(130,541)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(134,963)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(267,898)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(280,543)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest and other income, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,988&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,844&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,898&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,454&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127,553)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(124,119)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(256,000)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(257,089)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.68)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.72)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.37)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.50)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding, basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187,314,501</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171,449,847</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186,977,612</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171,336,568</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><div id="i62dfc679b4224d3aa92e28cb2b959584_19"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denali Therapeutics Inc.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.146%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201,530&#160;</font></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205,326&#160;</font></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term marketable securities</font></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">508,941&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">662,553&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,927&#160;</font></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</font></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,139&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,390&#160;</font></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,779&#160;</font></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">753,927&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">900,658&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term marketable securities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">229,534&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98,322&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,926&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,402&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease right-of-use asset</font></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,700&#160;</font></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,531&#160;</font></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</font></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,793&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,002&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible asset, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,250&#160;</font></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,825&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,939&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,157,955&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,144,854&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity </font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,807&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,276&#160;</font></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97,846&#160;</font></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90,083&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98,351&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liability, less current portion</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,026&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,210&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease liability, less current portion</font></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,479&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,532&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability related to the revenue participation right agreement </font></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205,189&#160;</font></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">322,777&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131,093&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders' equity</font></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">835,178&#160;</font></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,013,761&#160;</font></td><td style="background-color:#cceeff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,157,955&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,144,854&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor Contact&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laura Hansen, Ph.D.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hansen&#64;dnli.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Media Contact&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Erin Patton</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">epatton&#64;dnli.com</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>dnli-20260806.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019fd389-18b2-7284-ba9c-b5321995517e,g:d322ee95-5970-4db4-b30b-d93f59966936-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dnli="http://www.denalitherapeutics.com/20260806" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.denalitherapeutics.com/20260806">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2026" schemaLocation="https://xbrl.sec.gov/dei/2026/dei-2026.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dnli-20260806_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dnli-20260806_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.denalitherapeutics.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>dnli-20260806_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019fd389-18b2-7284-ba9c-b5321995517e,g:d322ee95-5970-4db4-b30b-d93f59966936-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityTaxIdentificationNumber_019fd389-18b2-75c8-80e1-ff0e7290baa7_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_019fd389-18b2-7055-99fd-c4b386497d8c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_019fd389-18b2-719f-9df4-e5499982cb0a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_019fd389-18b2-726d-97bd-aaab2be69d0d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019fd389-18b2-7e18-b4cc-f7f34ebdda63_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_019fd389-18b2-74e5-9bfe-02e77b561577_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019fd389-18b2-7ca4-a753-f0151831c13b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019fd389-18b2-7c3f-88e0-bcf41cdc3424_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019fd389-18b2-71a6-b62d-dd76ecc331a2_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019fd389-18b2-745d-8856-e5fc2c4072a1_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_019fd389-18b2-76c7-9eb8-10871f6998c3_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_019fd389-18b2-7d93-b2f6-c0e30bb7cf21_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_019fd389-18b2-774f-be52-fc5978d7b30f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_019fd389-18b2-7671-8292-178b808c2468_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_019fd389-18b2-788b-9242-324b1b35a9e2_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_019fd389-18b2-724c-9410-01b9726fc8a1_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_019fd389-18b2-79f7-9a04-d1b76bbba7eb_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019fd389-18b2-783d-89c4-b50850d7cd8d_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019fd389-18b2-7d89-adcf-a2297ced7625_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_019fd389-18b2-7bb9-9a3e-f628a7b9e95b_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019fd389-18b2-7583-900f-a3ca2dc1b167_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_019fd389-18b2-7505-8c4c-bd3119d05112_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>dnli-20260806_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019fd389-18b2-7284-ba9c-b5321995517e,g:d322ee95-5970-4db4-b30b-d93f59966936-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/Cover" xlink:type="simple" xlink:href="dnli-20260806.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019fd389-18b2-76e2-877d-ad9fb0c06312" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019fd389-18b2-7495-802a-d2ac6cda072b" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019fd389-18b2-76e2-877d-ad9fb0c06312" xlink:to="loc_dei_DocumentType_019fd389-18b2-7495-802a-d2ac6cda072b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019fd389-18b2-73d5-be52-2d31896fc07e" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019fd389-18b2-76e2-877d-ad9fb0c06312" xlink:to="loc_dei_DocumentPeriodEndDate_019fd389-18b2-73d5-be52-2d31896fc07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019fd389-18b2-7ecc-a995-95ad4ec7d6db" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019fd389-18b2-76e2-877d-ad9fb0c06312" xlink:to="loc_dei_EntityRegistrantName_019fd389-18b2-7ecc-a995-95ad4ec7d6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019fd389-18b2-7694-98c1-194e68d2db83" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019fd389-18b2-76e2-877d-ad9fb0c06312" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019fd389-18b2-7694-98c1-194e68d2db83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019fd389-18b2-7b52-a446-b1d7bda3bac1" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019fd389-18b2-76e2-877d-ad9fb0c06312" xlink:to="loc_dei_EntityFileNumber_019fd389-18b2-7b52-a446-b1d7bda3bac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019fd389-18b2-787f-93d8-179e64ad98d1" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019fd389-18b2-76e2-877d-ad9fb0c06312" xlink:to="loc_dei_EntityTaxIdentificationNumber_019fd389-18b2-787f-93d8-179e64ad98d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019fd389-18b2-7d22-afa8-ca1129a587e8" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019fd389-18b2-76e2-877d-ad9fb0c06312" xlink:to="loc_dei_EntityAddressAddressLine1_019fd389-18b2-7d22-afa8-ca1129a587e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019fd389-18b2-7471-aca4-049d0dc066b8" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019fd389-18b2-76e2-877d-ad9fb0c06312" xlink:to="loc_dei_EntityAddressCityOrTown_019fd389-18b2-7471-aca4-049d0dc066b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019fd389-18b2-7699-9c87-bcfaa8ba4358" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019fd389-18b2-76e2-877d-ad9fb0c06312" xlink:to="loc_dei_EntityAddressStateOrProvince_019fd389-18b2-7699-9c87-bcfaa8ba4358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019fd389-18b2-7577-8ac2-2eddfe0813bd" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019fd389-18b2-76e2-877d-ad9fb0c06312" xlink:to="loc_dei_EntityAddressPostalZipCode_019fd389-18b2-7577-8ac2-2eddfe0813bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019fd389-18b2-757d-9353-bd35dab7f553" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019fd389-18b2-76e2-877d-ad9fb0c06312" xlink:to="loc_dei_CityAreaCode_019fd389-18b2-757d-9353-bd35dab7f553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019fd389-18b2-7162-be5c-22bf9f17851e" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019fd389-18b2-76e2-877d-ad9fb0c06312" xlink:to="loc_dei_LocalPhoneNumber_019fd389-18b2-7162-be5c-22bf9f17851e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_019fd389-18b2-7692-b33e-1c2698289a31" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019fd389-18b2-76e2-877d-ad9fb0c06312" xlink:to="loc_dei_WrittenCommunications_019fd389-18b2-7692-b33e-1c2698289a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_019fd389-18b2-729c-815d-1b6dc2dc171b" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019fd389-18b2-76e2-877d-ad9fb0c06312" xlink:to="loc_dei_SolicitingMaterial_019fd389-18b2-729c-815d-1b6dc2dc171b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_019fd389-18b2-784e-b2c0-4b4226761d10" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019fd389-18b2-76e2-877d-ad9fb0c06312" xlink:to="loc_dei_PreCommencementTenderOffer_019fd389-18b2-784e-b2c0-4b4226761d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_019fd389-18b2-7609-b59c-c09d2cf6dc1b" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019fd389-18b2-76e2-877d-ad9fb0c06312" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_019fd389-18b2-7609-b59c-c09d2cf6dc1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019fd389-18b2-775f-a263-8471ac562e21" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019fd389-18b2-76e2-877d-ad9fb0c06312" xlink:to="loc_dei_EntityEmergingGrowthCompany_019fd389-18b2-775f-a263-8471ac562e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019fd389-18b2-70ca-806c-b88bba97506e" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019fd389-18b2-76e2-877d-ad9fb0c06312" xlink:to="loc_dei_Security12bTitle_019fd389-18b2-70ca-806c-b88bba97506e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019fd389-18b2-792b-a7f0-b00d55b4b068" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019fd389-18b2-76e2-877d-ad9fb0c06312" xlink:to="loc_dei_TradingSymbol_019fd389-18b2-792b-a7f0-b00d55b4b068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019fd389-18b2-70a5-83c8-c826d773268d" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019fd389-18b2-76e2-877d-ad9fb0c06312" xlink:to="loc_dei_SecurityExchangeName_019fd389-18b2-70a5-83c8-c826d773268d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019fd389-18b2-78a1-aca2-0d904fa3eed7" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019fd389-18b2-76e2-877d-ad9fb0c06312" xlink:to="loc_dei_EntityCentralIndexKey_019fd389-18b2-78a1-aca2-0d904fa3eed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019fd389-18b2-7c0d-9e8b-3f78bb9ab9f9" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019fd389-18b2-76e2-877d-ad9fb0c06312" xlink:to="loc_dei_AmendmentFlag_019fd389-18b2-7c0d-9e8b-3f78bb9ab9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>denali_greenlogo.jpg
<TEXT>
begin 644 denali_greenlogo.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_X@_P24-#7U!23T9)3$4  0$   _@87!P
M; (0  !M;G1R4D="(%A96B 'Z0 +  0 !P 5 #AA8W-P05!03     !!4%!,
M                        ]M8  0    #3+6%P<&P
M                                             !%D97-C   !4
M &)D<V-M   !M   !+QC<')T   &<    "-W='!T   &E    !1R6%E:   &
MJ    !1G6%E:   &O    !1B6%E:   &T    !1R5%)#   &Y   " QA87)G
M   .\    "!V8V=T   /$    #!N9&EN   /0    #YM;6]D   /@    "AV
M8V=P   /J    #AB5%)#   &Y   " QG5%)#   &Y   " QA86)G   .\
M "!A86=G   .\    "!D97-C          A$:7-P;&%Y
M
M                                ;6QU8P         G    #&AR2%(
M   4   !Y&MO2U(    ,   !^&YB3D\    2   "!&ED       2   "%FAU
M2%4    4   "*&-S0UH    6   "/'-L4TD    4   "4F1A1$L    <   "
M9FYL3DP    6   "@F9I1DD    0   "F&ET250    8   "J&5S15,    6
M   "P')O4D\    2   "UF9R0T$    6   "Z&%R       4   "_G5K54$
M   <   #$FAE24P    6   #+GIH5%<    *   #1'9I5DX    .   #3G-K
M4TL    6   #7'IH0TX    *   #1')U4E4    D   #<F5N1T(    4   #
MEF9R1E(    6   #JFUS       2   #P&AI24X    2   #TG1H5$@    ,
M   #Y&-A15,    8   #\&5N054    4   #EF5S6$P    2   "UF1E1$4
M   0   $"&5N55,    2   $&'!T0E(    8   $*G!L4$P    2   $0F5L
M1U(    B   $5'-V4T4    0   $=G1R5%(    4   $AG!T4%0    6   $
MFFIA2E     ,   $L !, $, 1  @ '4 ( !B &\ :@!ISNRW[  @ $P 0P!$
M $8 80!R &< 90 M $P 0P!$ $P 0P!$ "  5P!A '( ;@!A %, >@#M &X
M90!S "  3 !# $0 0@!A '( 90!V &X _0 @ $P 0P!$ $( 80!R '8 ;@!I
M "  3 !# $0 3 !# $0 +0!F &$ <@!V &4 <P!K .8 <@!M $L ; !E '4
M<@!E &X +0!, $, 1 !6 .0 <@!I "T 3 !# $0 3 !# $0 ( !A "  8P!O
M &P ;P!R &D 3 !# $0 ( !A "  8P!O &P ;P!R $P 0P!$ "  8P!O &P
M;P!R $$ 0P!, "  8P!O '4 ; !E '4 <B / $P 0P!$ " &109$!D@&1@8I
M!!H$/@0[!$P$/@1 !#X$,@0X!#D ( !, $, 1" / $P 0P!$ " %Y@71!>(%
MU07@!=E?:8)R $P 0P!$ $P 0P!$ "  30#@ '4 1@!A '( 90!B &X _0 @
M $P 0P!$!"8$,@0U!$($/00^!#D ( 06!!H +00T!#@$000_!#L$-00Y $,
M;P!L &\ =0!R "  3 !# $0 3 !# $0 ( !C &\ =0!L &4 =0!R %< 80!R
M &X 80 @ $P 0P!$"3 ) @D7"4 )*  @ $P 0P!$ $P 0P!$ " .*@XU $P
M0P!$ "  90!N "  8P!O &P ;P!R $8 80!R &( +0!, $, 1 !# &\ ; !O
M '( ( !, $, 1 !, $, 1  @ $, ;P!L &\ <@!I &0 ;P!+ &\ ; !O '(
M( !, $, 1 .( [,#QP/! \D#O .W " #OP.X \P#O0.W "  3 !# $0 1@#D
M '( 9P M $P 0P!$ %( 90!N &L ; !I "  3 !# $0 3 !# $0 ( !A "
M8P!O '( 90!S,*LPZ3#\ $P 0P!$=&5X=     !#;W!Y<FEG:'0@07!P;&4@
M26YC+BP@,C R-0  6%E:(        /-1  $    !%LQ865H@        @]\
M #V_____NUA96B        !*OP  L3<   JY6%E:(        "@X   1"P
MR+EC=7)V        !      %  H #P 4 !D '@ C "@ +0 R #8 .P!  $4
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MWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW__W!A<F$
M  ,    "9F8  /*G   -60  $]    I;=F-G=          !  $
M 0    $          0    $          0  ;F1I;@         V  "N%
M4>P  $/7  "PI   )F8   ]<  !0#0  5#D  C,S  (S,P ",S,
M &UM;V0        &$   H%+]8FUB                          !V8V=P
M       #     F9F  ,    "9F8  P    )F9@    (S,S0      C,S-
M   ",S,T /_N  Y!9&]B90!D      '_VP!#  P("!L*&R(1%R0J)!P;("0K
M*"@@)"DE)3$O)2DN*BLK.2LJ+B\T-34U-"\[.SL[.SL[.SL[.SL[.SL[.SL[
M.SO_VP!# 0T+"Q .$!L4&R0R*"$H,CLT,C(R.SL[.SL[.SL[.SL[.SL[.SM
M0$! 0#M 0$! 0$! 0$! 0$! 0$! 0$! 0$#_VP!# @T+"Q .$!L4&R0R*"$H
M,CLT,C(R.SL[.SL[.SL[.SL[.SL[.SM 0$! 0#M 0$! 0$! 0$! 0$! 0$!
M0$! 0$#_P  1" '%"&$# "(  1$! A$"_\0 'P   04! 0$! 0$
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M]?;W^/GZ_]H # ,   $1 A$ /P#U6BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** ,K6/$46D#,IY/11RQ_"N:?XG<X6'\WP?
MRVFN3UK4FU*5I2<AB<>FT' %4:=C-R9W/_"S_P#IC_Y$_P#L:/\ A9__ $Q_
M\B?_ &-<-13L+F9W/_"S_P#IC_Y$_P#L:/\ A9__ $Q_\B?_ &-<-118.9G<
M_P#"S_\ IC_Y$_\ L:/^%G_],?\ R)_]C7#446#F9W/_  L__IC_ .1/_L:/
M^%G_ /3'_P B?_8UPU%%@YF=S_PL_P#Z8_\ D3_[&C_A9_\ TQ_\B?\ V-<-
M118.9G<_\+/_ .F/_D3_ .QH_P"%G_\ 3'_R)_\ 8UPU%%@YF=S_ ,+/_P"F
M/_D3_P"QH_X6?_TQ_P#(G_V-<-118.9G<_\ "S_^F/\ Y$_^QH_X6?\ ],?_
M ")_]C7#446#F9W/_"S_ /IC_P"1/_L:/^%G_P#3'_R)_P#8UPU%%@YF=S_P
ML_\ Z8_^1/\ [&C_ (6?_P!,?_(G_P!C7#446#F9W/\ PL__ *8_^1/_ +&C
M_A9__3'_ ,B?_8UPU%%@YF=S_P +/_Z8_P#D3_[&C_A9_P#TQ_\ (G_V-<-1
M18.9G=)\3L]83^#Y_P#915N'XD0M]Y''TP?ZBO.J,46#G9ZU9^+[:ZX60 ^C
M97^=:R2AQN!R/;G^5>'^U6K+4Y;$[HG9?H3C\CP:5BE,]HW4M<%I/Q&(^6X7
M(_O)U_$5VEEJ*7RB2)@RGN/\\4K%)W+5%%% PHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *2EI": "C-0SW2VX+N0%'4D\5R>K_$
M5(OEMQN/]YN%_ =_TH%='8!ZH7GB&"S^_(H/H#D_D,FO+]1\13ZAQ(YQ_='"
M_D/ZUFXSUY^M.Q+F>F3_ !#MH_N[F^BX_F15-_B9&.D;?B0/\:\_H%.PN=G?
M_P#"RT_YY'_OH?X4?\++3_GD?^^A_A7 8HQ2L'.SO_\ A9:?\\C_ -]#_"C_
M (66G_/(_P#?0_PK@,48HL+G9W__  LM/^>1_P"^A_A1_P ++3_GD?\ OH?X
M5P&*,46#G9W_ /PLM/\ GD?^^A_A1_PLM/\ GD?^^A_A7 8HQ18.=G?_ /"R
MT_YY'_OH?X4?\++3_GD?^^A_A7 8HQ18.=G?_P#"RT_YY'_OH?X4?\++3_GD
M?^^A_A7 8HQ18.=G?_\ "RT_YY'_ +Z'^%'_  LM/^>1_P"^A_A7 8HQ18.=
MG?\ _"RT_P">1_[Z'^%'_"RT_P">1_[Z'^%<!BC%%@YV=_\ \++3_GD?^^A_
MA1_PLM/^>1_[Z'^%<!BC%%@YV=__ ,++3_GD?^^A_A1_PLQ/^>3?]]#_  K@
M,48HL'.SO_\ A9B?\\F_[Z'^%'_"S$_YY-_WT/\ "N HHL'.SO\ _A9B?\\F
M_P"^A_A6SH_BV'53L7*OC[K\$_2O)Z?%*82'4X(.01USZT6*4F>X YI:IZ/>
M_;H4G[NH)QTSW_6KE(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ I*#3=U #J:&K#UGQE!IN5SO<?PKS^9Z#^=<7J?CBXO,JI\M?1>I^IY_3%!
M+E8])NM1CM!F1E7_ 'B!61<^.[6#HQ;_ '5/\S@?K7ETDIE.6))]3R?SIM.Q
M/.>AR?$N$?=1S]<#^1-1?\+,7_GD?^^Q_A7 T4["YV=[_P +-7_GD?\ OL?X
M4O\ PLU?^>1_[['^%<#1BBP<[.^_X6:O_/(_]]C_  H_X6:O_/(_]]C_  K@
M<48HL'.SOO\ A9J_\\C_ -]C_"C_ (6:O_/(_P#?8_PK@<48HL'.SOO^%FK_
M ,\C_P!]C_"C_A9J_P#/(_\ ?8_PK@<48HL'.SOO^%FK_P \C_WV/\*/^%FK
M_P \C_WV/\*X'%&*+!SL[[_A9J_\\C_WV/\ "C_A9J_\\C_WV/\ "N!Q1BBP
M<[.^_P"%FK_SR/\ WV/\*/\ A9J_\\C_ -]C_"N!Q1BBP<[.^_X6:O\ SR/_
M 'V/\*/^%FK_ ,\C_P!]C_"N!Q1BBP<[.]_X6:O_ #R/_?8_PI?^%F+_ ,\C
M_P!]C_"N!HHL'.ST./XEPG[R./I@_P R*T;;QQ:S\;MI]&4C]>GZUY728I6'
MSGMEM?I=#=&RL/\ 9.?Y5/NKQ"*0PG<I(/J"0?SKH=+\=SV?RR?.HZ[N#_WU
M_C18:G<]/HS6'HWB^'5,*IVN?X6Z_@>AK:W4B]Q]%(*6@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** *UY?+9H99"%5>I-<M<?$J-#A(V(]20O^-9/Q#U RRBW_
M (8P#^)Y_D17)XII$2EJ=]_PLU?^>1_[['^%'_"S5_YY'_OL?X5P.*,4[$\[
M.^_X6:O_ #R/_?8_PH_X6:O_ #R/_?8_PK@<48HL'.SOO^%FK_SR/_?8_P *
M=%\3(R<-&P^A!_F!7G^* <46#G9Z_I7B2'4^(V^;^Z>&_+_#BM/=7A\<AB(9
M205Z$=1^->E^#_$G]JJ8Y/\ 6IU]QG@_X_\ UZ31:D=/1112*"BBB@ HHHH
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MZ8'->&X[UV?AOQT8BL%R<@]'[\],TFBXR/0:*8K[N1SGTI](L**** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8/CD9LY?\
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MZ:BBBD6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >>_$S_61_[A_G7&UV7Q,_UD?^X?YUQM4C.6X4444$A1110 44
M44 =!X$_X^T^C_\ H)KU.O+/ G_'VGT?_P!!->IU+-(;"T444%!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !6#XX_X\Y?^ ?^AK6]6#XX_P"/.7_@'_H:
MT">QY2:*#13,@HHHI@%%%% !6[X'_P"/R+_@?_H#5A5N^!_^/R+_ ('_ .@-
M0-;GJ]%%%2:GA=%2W=N;9VB;JI(_*HJHQ"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M4\.:N=*F67/RG ;Z'K6710&Q[DK9Y[4ZN=\%ZG]NMU!^]&=I_#!'Z'^==%4F
MR=PHHHH **** "BBB@ HHHH **** "BBB@ I*6J]]="T1I6Z(I/Y4 <'\0=:
M\YQ:+T09;ZD9 _ ?SKCS4MS<M<,TK'YF))_$YJ*J,I.["BBB@04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !0!10#0!ZYX0_P"/2+_=_J:V*R_#,!@MHD;J$'Z\_P!:U*DV"BBB@ HH
MHH **** "BBB@ HHHH **** $-8OBG5_[,@9Q]YOE7ZGO^%;5>:_$#4OM$X@
M!XB X[9/)_2@3=CEV)8DGO24451D%%%% !1110 4444 %%%% !1110 4444
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M&O7:Y?QYI/VR#S5'S1<_\![C\.OX4)DR5SS2BC&>:*HS"BBB@ HHHH ****
M.@\$ZO\ 8)PK'Y9?E/L>@/Y\?2O4LFO#@V.1UKUOPSJW]IP++_$!AOJO^-)E
MP9L4444BPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** //?B9_K(_]P_SKC:[+XF?ZR/_ '#_ #KC:I&<MPHHHH)"BBB@ HHH
MH Z#P)_Q]I]'_P#037J=>6>!/^/M/H__ *":]3J6:0V%HHHH*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "L'QQ_QYR_\ _\ 0UK>K!\<?\><O_ /_0UH
M$]CRDT4&BF9!1113 **** "MWP/_ ,?D7_ __0&K"K=\#_\ 'Y%_P/\ ] :@
M:W/5Z***DU$Q12T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ"TF7 6BEHI%B44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M%
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M *":]3J6:0V%HHHH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L'QQ_Q
MYR_\ _\ 0UK>K!\<?\><O_ /_0UH$]CRDT4&BF9!1113 **** "MWP/_ ,?D
M7_ __0&K"K=\#_\ 'Y%_P/\ ] :@:W/5Z***DU"BBB@ HHHH **** "BBB@
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M *&M;U8/CC_CSE_X!_Z&M GL>4FB@T4S(****8!1110 5N^!_P#C\B_X'_Z
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M% 'J_@?_ (\XO^!_^AM6[6%X'_X\XO\ @?\ Z&U;M2;(**** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHHH **** "BBB@#B/B9TB_X'_-*X*N]^)G2+_@?\TK@JI&<MPHHHH)"BBB@
MHHHH LZ9_K8_]]?YBO:A7BNF?ZV/_?7^8KVH4F7 6BBBD6%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 )1110!X=+U/UIM.EZGZTVJ,0HH
MHH **** "BBB@#U?P/\ \><7_ __ $-JW:PO _\ QYQ?\#_]#:MVI-D%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 )FH9[D0*7/0"I<5S_
M (EN\8A'KDU$Y\JN72ASR43"GE,Q+'JQIE%%>>]3UTK"T444AA1110 4444
M)6OX<L_-<R'HO\SR/TK(Q7::79_98PO?'/UK:A3O*YRXNKRPY>I=Q1BEHKN/
M."BBB@ HHHH **** ,CQ)I7]IP-%_%U7ZC_ZV1]#7D9&#C_/TKW'%>7^.=(^
MPS[U^[*"P] 1]X4T1-'.T444R HHHH **** "C-%% 'I7@+5_M</D-]Z+ _X
M"?N_ETKJ<UY#X9U;^S)UD)^4\-]#_AQ^5>N@YI,UB[H=1112&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!Y[\3/]9'_N'^=<;79?$S_61_[A_G
M7&U2,Y;A11102%%%% !1110!T'@3_C[3Z/\ ^@FO4Z\L\"?\?:?1_P#T$UZG
M4LTAL+11104%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8/CC_CSE_P"
M?^AK6]6#XX_X\Y?^ ?\ H:T">QY2:*#13,@HHHI@%%%% !6[X'_X_(O^!_\
MH#5A5N^!_P#C\B_X'_Z U UN>KT445)J%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q?Q+_ -7%_OG^
M5>?UZ!\2_P#5Q?[Y_E7G]4C.>X4444$A1110 4444 /M_O+]1_.O<:\.M_O+
M]1_.O<:3+AL%%%%(L**** "BBB@ HHHH **** "BBB@ KRKQU_Q]R?1/_0!7
MJM>5>.O^/N3Z)_Z *:)GL8%%%%,S"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /2?AS_Q[-_UU
M;_T%:ZH5ROPY_P"/9O\ KJW_ *"M=4*DU0M%%% PHHHH **** "BBB@ HHHH
M **** "BBB@#B/B9TB_X'_-*X*N]^)G2+_@?\TK@JI&<MPHHHH)"BBB@ HHH
MH LZ9_K8_P#?7^8KVH5XKIG^MC_WU_F*]J%)EP%HHHI%A1110 4444 %%%%
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M_4?SKW&DRX;!1112+"BBB@ HHHH **** "BBB@ HHHH *\J\=?\ 'W)]$_\
M0!7JM>5>.O\ C[D^B?\ H IHF>Q@4444S,**** "BBB@ HHHQ0 44?C1B@84
M48HQ0(**,48H **,48H **,48H **,48H **,48H **,48H **,48H **,48
MH **,48]Z "BC'O5O3-+DU)Q'$"?4]A[D]J+CLSOOATI%L3ZR-_)1_2NJJAH
M^FC3HE@!^Z.3ZD]35^I-$A:***!A1110 4444 %%%% !1110 4444 %%%% '
M$?$SI%_P/^:5P5=[\3.D7_ _YI7!52,Y;A11102%%%% !1110!9TS_6Q_P"^
MO\Q7M0KQ73/];'_OK_,5[4*3+@+1112+"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** $HHHH \.EZGZTVG2]3]:;5&(4444 %%%% !1110!
MZOX'_P"/.+_@?_H;5NUA>!_^/.+_ ('_ .AM6[4FR"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH 3--:3:,GM3JQ_$5YY*;!U;^0ZU,Y<L;E0@YR
M2.>O[K[4Y<]R,?057HHKSFVW<]B*4586BBBD,**** $S1FBB@ J_HMG]ID /
M1>3_ $K/S^M=;H-G]G3/=L&M*$.>1SXFIR0OU9J[:,4M%>@>8%%%% !1110
M4444 %%%% !1110!S?C;2/[0@+*/GB^8>X[C\N:\OKW$IGBO(_$VE'3)VB'W
M2=R_[I_PIHB:,JBBBF0%%%% !1110 4444 >L>$]7_M.!7/WD^5OJ!U_$5MU
MY=X'U?[#/L8_)+\OT;L?YC\:]0-)FJ=T.HHHI#"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#SWXF?ZR/_</\ZXVNR^)G^LC_ -P_SKC:I&<MPHHHH)"B
MBB@ HHHH Z#P)_Q]I]'_ /037J=>6>!/^/M/H_\ Z":]3J6:0V%HHHH*"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+%'^Q(/^>2?]\+_A1_8D'_/)/^^%_P *O44!8H_V)!_SR3_OA?\ "C^Q(/\
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M0 4444 6=,_UL?\ OK_,5[4*\5TS_6Q_[Z_S%>U"DRX"T444BPHHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+/ G_'VGT?\ ]!->IU+-(;"T444%!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !6#XX_X\Y?\ @'_H:UO5@^./^/.7_@'_ *&M GL>4FB@T4S(****8!11
M10 5N^!_^/R+_@?_ * U85;O@?\ X_(O^!_^@-0-;GJ]%%%2:A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 <7\2_P#5Q?[Y_E7G]>@?$O\ U<7^^?Y5Y_51,Y[A11102%%%% !1110
M^W^\OU'\Z]QKPZW^\OU'\Z]QI,N&P4444BPHHHH **** "BBB@ HHHH ****
M "O*O'7_ !]R?1/_ $ 5ZK7E7CK_ (^Y/HG_ * *:)GL8%%%%,S"BBB@ HHH
MH *[+X:?ZR3_ '!_.N-KLOAI_K)/]P?SH8X[GH-+24M2:A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M37J=>6>!/^/M/H__ *":]3J6:0V%HHHH*"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "L'QQ_QYR_\ _\ 0UK>K!\<?\><O_ /_0UH$]CRDT4&BF9!1113
M **** "MWP/_ ,?D7_ __0&K"K=\#_\ 'Y%_P/\ ] :@:W/5Z***DU"BBB@
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M_/1_^^C_ (T?VE+_ ,]'_P"^C_C187.>TYHS7BW]I2_\]'_[Z/\ C1_:4O\
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M?^ C=7KM>>_#>QW.\YZ*H4?5N3^@_6O0J3-(+0****104444 %%%% !1110
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MX$RAUY##(/L1FO$?>O1/A]JOGQ&V)^:(\?[I_P #^F*&BX,["BBBI+"BBB@
MHHHH **** "BBB@ HHHH Y'XCVQD@60?P.,_0@C^>*\YKV'Q%8_;H)(NY7CZ
MCD5X]FFC.>X4444R0HHHH **** #ISWKIO"OB_\ LL>1+S'G@\Y7\.XKF:*
M3LSVFPU..^7?$P8>W]1VJSFO#T<QG*G!'IQ4W]I2_P!]O^^C_C2L7SGM6:,U
MXM_:4O\ ST?_ +Z/^-']I2_\]'_[Z/\ C18.<]IS1FO%O[2E_P">C_\ ?1_Q
MH_M*7_GH_P#WT?\ &BP<Y[3FC->+?VE+_P ]'_[Z/^-']I2_\]'_ .^C_C18
M.<]IS1FO%O[2E_YZ/_WT?\:/[2E_YZ/_ -]'_&BP<Y[3FC->+?VE+_ST?_OH
M_P"-']I2_P#/1_\ OH_XT6#G/:<T9KQ;^TI?^>C_ /?1_P :/[2E_P">C_\
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M4 %8/CC_ (\Y?^ ?^AK6]6#XX_X\Y?\ @'_H:T">QY2:*#13,@HHHI@%%%%
M!6[X'_X_(O\ @?\ Z U85;O@?_C\B_X'_P"@-0-;GJ]%%%2:GALDID8N>K$D
M_CUIM%%48A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 48HK:\(Z+_:<XSRD>&;TX/ _'
MI^?I0.UV=]X2TS[!;HA^\PW-]6YQ^ K<INVG5)J%%%% !1110 4444 %%%%
M!1110 4444 %07=N+A6C;HP(/X\5/24 >)7EHUK(T+=48@_A_CU^E0UV?Q#T
M<JPO%Z-A6QV(Z'\1Q^ ]:XRJ1DU9A1110(**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HS110!Z_P"%
MIC-:Q,W78/TXK5K'\(?\>D7^[_4UL5)JM@HHHH&%%%% !1110 4444 %%%%
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M&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7ER]AU%%%=)RA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M><O_  #_ -#6MZL'QQ_QYR_\ _\ 0UH$]CRDT4&BF9!1113 **** "MWP/\
M\?D7_ __ $!JPJW? _\ Q^1?\#_] :@:W/5Z***DU/"Z***HQ"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***T='T";53B->.['A1^//Y=: 6I0BC,Q"J"23@ =:] \.>!A;;9Y^7'
M(7^$?7U/Z5JZ!X7CTD9'S2$<N1^@]!_/N:VRN:39HHBXI:**104444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !32G>G44 <QXI\*+J@\V/B8?DV.@
M/H?0UYK<0-;L8W!# X(/^?R]:]OQ61KWAR/6%PW#@<,.OT/J*:9$HGDE%:FL
M^'9M*/SC*]F7E?\ ZQ]CCVSUK+_STID:H**** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 )BD*YIU% 'DGBW2/[-G8
M81_F7TP3R/P-8U>F^.-(-]!O49>(EOJ/XA_(_A7F7\JI&35F%%%% @HHHH *
M*** "M[P9J_]GS@'[DHVGT'/!_/]*P:.E ;'N:G-+69X9O3>VT<IZE<'ZJ2I
M_E6G4FP4444 %%%% !1110 4444 %%%% #2*R]>T%-838PPR\JW<'_ ]Q6M3
M=N: /&=5TJ337,4HP>Q[$>H/?^?K[TZ]GU+28]10Q2KD?J/<'_.>]>=:]X+E
MT[+QY>/U Y'U'I[C\J:9FXG.T4#_ #_GM_GBBF2%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7H/PS_U<O\
MOC^5>?5Z#\,_]7+_ +X_E0RH;G9T445)H%%%% !1110 4444 %%%% !1110
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M_P!Z3_OI?_B*/^%;6_\ >D_[Z7_XBBX<AYO17I'_  K:W_O2?]]+_P#$4?\
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MY/(SS7%&*]*_X5Q;>K_FO_Q-'_"N+;U?\U_^)HN'(SS7% %>E?\ "N+;U?\
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M]7_-?_B:/^%<6WJ_YK_\31<.1GFN*,5Z5_PKBV]7_-?_ (FC_A7%MZO^:_\
MQ-%PY&>:XHQ7I7_"N+;U?\U_^)H_X5Q;>K_FO_Q-%PY&>:XHQ7I7_"N+;U?\
MU_\ B:/^%<6WJ_YK_P#$T7#D9YKBC%>E?\*XMO5_S7_XFC_A7%MZO^:__$T7
M#D9YKBC%>E?\*XMO5_S7_P")H_X5Q;>K_FO_ ,31<.1GFN*,5Z5_PKBV]7_-
M?_B:/^%<6WJ_YK_\31<.1GFN*,5Z5_PKBV]7_-?_ (FC_A7%MZO^:_\ Q-%P
MY&>:XHQ7I7_"N+;U?\U_^)H_X5Q;>K_FO_Q-%PY&>:XHQ7I7_"N+;U?\U_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 06, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  06,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Denali Therapeutics Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-3872213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">161 Oyster Point Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">866-8547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DNLI<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001714899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="dnli-20260806.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="dnli-20260806.htm">dnli-20260806.htm</File>
    <File>dnli-20260806.xsd</File>
    <File>dnli-20260806_lab.xml</File>
    <File>dnli-20260806_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2026</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "dnli-20260806.htm": {
   "nsprefix": "dnli",
   "nsuri": "http://www.denalitherapeutics.com/20260806",
   "dts": {
    "inline": {
     "local": [
      "dnli-20260806.htm"
     ]
    },
    "schema": {
     "local": [
      "dnli-20260806.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2026/dei-2026.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "dnli-20260806_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dnli-20260806_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2026": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2026": 22
   },
   "report": {
    "R1": {
     "role": "http://www.denalitherapeutics.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dnli-20260806.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dnli-20260806.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentType",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001714899-26-000096-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001714899-26-000096-xbrl.zip
M4$L#!!0    ( &B@!EU9936A'1   $!Y   1    9&YL:2TR,#(V,#@P-BYH
M=&WM75M3XS@6?I]?H<WL3D,5=GS)S0&RE0GIV>QT T7HFJE]V5)LA6C:L=VR
M#,G^^CU'MG,A"1@(!+KIAYG8DJ6CHZ/OW"1Q],_)V"?73,0\#(X_F+KQ@;#
M#3T>7!U_:/<[O=Z'?[9^.OJ;IOWYZ\4G<A*ZR9@%DG0$HY)YY(;+$9$C1OX(
MQ5=^3<FY3^4P%&--2S_KA-%4\*N1))9AU?)J>:EH&J8S].R&HYF-@:75K49%
M&U#'U095VS(=IUHUZ^S@JNG9EL684]6J3MW0*MX JMG&0/,<>UAUG%K-L6L'
M7G-H-* )HU8?TDK%M*H#=V#; ]L=#@V#UJJ.ZG<D8<PP[B ^+HVDC)KE\LW-
MC7YCZZ&X*D.G3GF"=4III2:?2"UF[E)E>-:OPNLR#WP>,.1-60H:Q#AT*H&9
M9<LPJYK1T&QSWLY2$Y.!\%6/4-->:&BAV_7U[^K3,C3#TDPK;V02\W6#M S#
M+/_Y^5/?';$QU7@02QJX+/_*8_.O5+?Y<*$ .ZG-FH="OFE4!HYJN6$@_.L=
MU;%X0.-9]<E*_:5)PE)5M>E3D-<2"[0O_5+K:,2HUSH:,TD)?JJQ;PF_/BYU
MPD""[&J7TPAZ<-.GXY)D$UE6\UUN_?333T>22Y^U/&"RAD,U0)R.RNG+HW+:
M]"#TIJTCCU^36$Y]=ESR>!SY=-H,PH ! 7S2Q(I,I#^YY[% _83R4UA @KMI
M_Q-YP8;')5<#(0GH&%MBO-D-H+MI!Z@3U.\%'IO\SJ8EPKWCTE"SS%++@.FK
MFY6&XQR5EUI]0"=M6,<>KN6//KTJD52(CDL@=<TAGS!/&U(?9R+KU2JU/K8_
M];LK'9:71RC8D F $!:OF1B<L&:L9 Y((FH"FQ*FX[@4\W'DX\2K=R.!%"_-
M@3Z)/9@AU=^\DZS/.$R$>E("V<R&K6C'8>?OF6)L_L0]?!YR)HBBB:U=X9W>
M[\L,O_UQ*W^UW'H$[ F]_ F6@9 G )DM' _B DK5[;(9F=Z&JGE)_IQW4EX:
M=\ZD&5?*"P)9!K%-91>YP^]#S/\B]^;?9/(^YH$V8@CK3;,1R<,;[LE1TS2,
M?Y14O=91'%$0B(' &4M_IXW,FFH=23KP6=[B(!1 GN:&OD^CF#7S'X?YTDI1
M3U,?'8ZIN (2!J&4X;A9!0I ATGN4E^C/K\*FLB&K'A.G&ZD!$I@@_3RGK-B
M'8K*J^^=ANX8ZXL,W53ORZH]D1=F?+$C65+?P$B0 <<ENW1KL!GY5B1)'/K<
M(S\;ZM]A5B[#J&FN%$;40_7<- B4S?HO*\:LFZJ45=@6SI1B3,HC%P26B5(Z
M5WEUH#84S;RO(0@4 ,&8^]/FA[;@U/]P$(/* 7TH^# MCOG_6-,RH&WU>),.
MOPY?JPG+Q<1"UG\Y[5UV3TC_LGW9[2\+Q@+)NZ6QW^U\N>A=]KI]TCX](=T_
M._]JG_[6)9VSSY][_7[O['0CX<MB"?-ZN,!]Z_FX;YJ%1O8'C4<@.3(,#LB)
MWM'!)*M6G'PT;V(YF@V]WK#O7(Z%F[+TBE/;2E.VJ3N5NT%B!U0I7E6W#%TK
MZ/.D:LM N(QUJT"W78H*PV:MP,(=4/?KE0B3P-.R-3Q4_PZ?%ZL^GEU\)L5M
MOMQ]2RW@U+(#_=[0?E\UZ]Y!X1T4=@H*J];/;A%A$P2LLW*?WY@QK4(  :;,
M1??TDEQTS\\N+N\S7(JBW?/2?)Z(.*&!)#(D?>9B9..7G\V:<6C:)!3$K.YY
M^Z^4W>%0!<. ZD1PR<$)[D[<$?C C+1=2:#8=.S*VY@&=#21X@L6A4*2O?R9
M47 U62P)N\9(H%#%S-MODL?9Q96=C_3A"O1<^=W=U!M?#IYX\$8;0Q,C_$SS
MZ%2; LLT%LQB*:56.[E*8IE*=>U A4;?-?"[!GYE&OAUF^7/B!L%K>^'1G0O
MV!6/,60O3Z$DAP,;H)8%, AR.6*"1BR!)1J37N#JFS#A'H!]1LXT"C%FKSNA
MH.YP_*@QQ&S<A,8DCIB+@5./\(!P&1-0D*! Q/X[XKTCWKO/<:\U^R:6APU?
M/5 0-[VW]+JUG87V6HFJURM%%L=],F7I-4PEH/R:>C7]M:H'5J8\C%Y(-1B/
MT9F@!D,!'H9*</<E&->=, FDF'9";]GRQAP]YM(DBT1XC>W,3>X*ZEB?WE#!
M-NI4Z6UI;7^7\_"1^PPJ#P"",IY6,2UJ:G;#-LUWICZ*J9=TTLORR*X2\&4.
MUTJM2@T87+<LT[Z3Q<^*$*D^>$D^[JF%CL&>4()-3/Y*!(\]KD)!8%"^%NG:
M 6,ZX7C,8]RM]0,SH:=?Z'V==,>1'TZ9>+F5\,)PPA=UW_YKF? 79@(J'I+B
MXH_*@F4=04Y#?7]5YHN$3$SC&6.MSQ,S:7N>8'&<_>\3M&?FZK%>:IDUDYQ-
M8Q@$.0]Y(,FO_K57/&SR)EG1@9]GXC*\F5FWC5*K'R9R1/I ^D=! Y?';GB;
M"P</2!0O=:B4\9DX!ZN:J[V<!8UNI]3J '.A=L#I;6H>2\QY"+WY_^%1:O]G
M.6RCU'(J1L/8-/,O%ODB6^QQ18PJ=W?Y4N)=, :831@& ",!@L,CZA,V86XB
M^37&!0'06'Q H,A/$(S)_W@$<N"QAV?W=I2#+;;.]XJ+.J[MMF!T2;C-4JM6
M71'M_0>LH$\AZ*[S41C<<N%,J]1JU&I:HUJI[QHT"TK5/(;^R\\-RZP?QD0R
MGT4X.!*HT2V*%#C\]'N4J=-0DG84^6 3@-9_,WF!CZ Y0%>GB0&A% D\TA0I
M8-Z&),V6>R1&54-\&N<9YO@]/_">'WC/#VRT[>_:7GP/E*V@Q'8PP2EDOG1&
MS/VJ=LW0"&Q(,!4P]#,()V3 _/ &,0$+$3E(0_N=#+F/P,YC0'G) @^P0H8
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M8<V2PSW;_3_916_8+?AB] =02P,$%     @ :* &7;U2[^8H"0  ?50  !4
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MPLXC])J#N!B83O]1':D*12OM*<'JJ*B;*;SJMH%1JVVTB#<*5*)I['. ,2*
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M2]!?1YZ]@/],PYGS^_\!4$L! A0#%     @ :* &75EE-:$=$   0'D  !$
M             ( !     &1N;&DM,C R-C X,#8N:'1M4$L! A0#%     @
M:* &74A2VHUE @  %P<  !$              ( !3!   &1N;&DM,C R-C X
M,#8N>'-D4$L! A0#%     @ :* &7;U2[^8H"0  ?50  !4
M ( !X!(  &1N;&DM,C R-C X,#9?;&%B+GAM;%!+ 0(4 Q0    ( &B@!ETW
M '0SXP4  /(P   5              "  3L<  !D;FQI+3(P,C8P.# V7W!R
M92YX;6Q02P$"% ,4    " !HH 9=&(+,V(,J   /P $ &P
M@ %1(@  97@Y.3%P<F5S<W)E;&5A<V5Q,C(P,C8N:'1M4$L%!@     %  4
*30$   U-      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>dnli-20260806_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="dnli-20260806.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <startDate>2026-08-06</startDate>
            <endDate>2026-08-06</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001714899</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2026-08-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Denali Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38311</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">46-3872213</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">161 Oyster Point Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">866-8547</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">DNLI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
